img

Title: Treatment of vitiligo patients with high doses of oral vitamin D3 combined with melanocyte stimulation and pigment cell transplantation is safe and efficacious

Ulrich Amon

International Center for Skin Diseases DermAllegra, Germany

Biography

Professor Amon studied law and medicine at the Universities of Innsbruck, Freiburg i. Br, Marburg and the Guy's and St. Thomas's Medical School, London, England. Post-Doctoral Fellowship in the Department of Experimental Dermatology at Hoffmann - La Roche in Basel. Dermatological training at the Department of Dermatology Medical University of Lübeck. Direction of a laboratory for experimental allergology. 1996-2012 Medical Director of the Dermatology Clinic Hersbruck (Nuremberg). Parallel in 2005, founding of the DermAllegra International Center for Skin Diseases, a private practice clinic in Pommelsbrunn-Hohenstadt (Nuremberg). There, Professor Amon is now working full-time and additionally heads a center for clinical trials there. Clinical priorities are autoimmune and inflammatory skin diseases and laser surgery. Another activity and research focus is the micronutrient medicine and vitamin D.

Abstract

Vitiligo is a complex autoimmune skin disease resulting in varying patterns and degrees of depigmentation. The genetic and etiologic background are thought to be multifactorial. As in other autoimmune diseases regulation of immune dysfunctions through vitamin D seems to be important also in vitiligo. A recent meta-analysis revealed that vitamin D receptor (VDR) Apal polymorphism increased the susceptibility risk of vitiligo. Our own work demonstrates a correlation of BsmI VDR polymorphism in > 60 % of all vitiligo patients. We and others have shown a positive correlation between serum 25(OH)D deficiency and the incidence of vitiligo. Using these pathogenetic facts in our Vitiligo Center, we are prescribing high doses of oral vitamin D3 according to Finamor DC et al. (Dermatoendocrinol 2013; 5:222-34). Patients are receiving oral vitamin D3 supplements of 20.000 to 60,000 IU once daily according to their body weight and their parathormone level at baseline for at least six months in association with a low-calcium diet (avoiding dairy products and calcium-enriched foods like oat, rice or soya “milk”) and sufficient hydration (minimum 2.5 L daily). As published before, also in our sample serum creatinine and calcium does not change significantly and urinary calcium excretion only increases within the normal range. Combining oral vitamin D3 with subsequent melanocyte stimulation using UVB 311 nm irradiation stabilization of vitiligo can be reached in > 95 % of all patients. Pigment cell transplantation using non-cultured melanocyte cell suspensions is the further step in our treatment protocol for selected patients.

The presentation will show that our therapeutic strategy for vitiligo using oral high-dose vitamin D3 therapy is very effective and safe for vitiligo patients.

Audience take away:

  • The audience will be able to use high doses of oral vitamin D3 for vitiligo and other autoimmune diseases
  • The audience will be able to evaluate the potential risks of high doses of vitamin D3 as well as using safety criteria in their own daily practice or clinic
  • The audience will be able to use an effective treatment combination for vitiligo patients leading to significant improvement of satisfaction of both patients and physicians